title: The role of phospholipase in beta-agonist-induced down regulation in guinea pig lungs.
abstract: It has been observed that repeated and prolonged beta-agonist treatment causes the impairment of beta-adrenergic function, so-called "desensitization" or "down regulation". To clarify the mechanism of down regulation, the following experiment was performed using guinea pig lungs. Animals were divided into four groups: In the metaproterenol groups, guinea pigs were treated with metaproterenol (10 mg/kg/day) by intraperitoneal injection once a day for 1 day or for 7 successive days In the control groups, guinea pigs were treated with saline by the same procedure as in the metaproterenol groups. In the group treated with metaproterenol for 7 days, there was a 45% reduction in the number of beta-adrenoceptors and a 62% reduction in adenylate cyclase activity, compared with those of the control group. However, there were no significant changes in the dissociation constant (Kd) of the receptors. On the other hand, no reduction in the number of beta-adrenoceptors and adenylate cyclase activity was observed in the group treated with metaproterenol once a day for 1 day, compared with those of the control group. Phospholipase (PLase) activity in the lung microsomes of guinea pigs injected with metaproterenol for 1 day and for 7 days was elevated by 14.4 and 33.1%, respectively, compared with that of the control groups. Phospholipid contents of lung membranes prepared from the animals treated with metaproterenol for 7 days were significantly decreased compared with those of the control group, though in the group treated with metaproterenol once a day for 1 day, phospholipid contents did not differ from those of the control. Lung membranes treated with PLase A2 revealed decreases both in the number of beta-adrenoceptors and adenylate cyclase activity, dose dependently. These results and the fact that membrane phospholipids are involved in the beta-adrenoceptor system suggest that down regulation observed during beta-agonist administration is, at least in part, attributed to degradation of phospholipids of lung membranes by the persistent activation of PLase in the tissue.
mesh_terms: D000262:Adenylyl Cyclases / Q000378:metabolism; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000818:Animals; D001665:Binding Sites / Q000187:drug effects; D004082:Dihydroalprenolol / Q000378:metabolism; D006168:Guinea Pigs; D008168:Lung / Q000187:drug effects / Q000201:enzymology*; D008297:Male; D008563:Membrane Lipids / Q000032:analysis; D009921:Metaproterenol / Q000494:pharmacology; D008861:Microsomes / Q000201:enzymology; D010740:Phospholipases / Q000502:physiology*; D010741:Phospholipases A / Q000494:pharmacology; D010743:Phospholipids / Q000032:analysis; D011943:Receptors, Adrenergic, beta / Q000187:drug effects / Q000502:physiology
chemical_list: D000318:Adrenergic beta-Agonists; D008563:Membrane Lipids; D010743:Phospholipids; D011943:Receptors, Adrenergic, beta; D009921:Metaproterenol; D004082:Dihydroalprenolol; D010740:Phospholipases; D010741:Phospholipases A; D000262:Adenylyl Cyclases